US46266A1097
US46266A1097
iRadimed Corporation
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 1.12B EUR | 1.22B EUR | 1.23B EUR | 1.24B EUR |
Enterprise Value | 1.04B EUR | 1.16B EUR | 1.17B EUR | 1.19B EUR |
Valuation Multiples | ||||
Trailing P/E | 48.85x | 53x | 52.12x | 69.88x |
Forward P/E | 35.65x | -- | -- | -- |
Price to Sales | 12.95x | 14.15x | 14.26x | 19.34x |
Price to Book | 10.99x | 12.01x | 12.49x | 13.14x |
EV/Revenue | 12.04x | 13.47x | 13.61x | 18.54x |
EV/EBITDA | 35.6x | 39.84x | 39.96x | 54.97x |
Price to FCF (P/FCF) | 69.04x | 49.78x | 51.33x | 76.99x |
EV/FCF | 64.16x | 47.37x | 48.98x | 73.82x |
FCF Yield | 1.45% | 2.01% | 1.95% | 1.3% |